NOVARTIS

The Brain Tumor Therapeutics Market is projected to grow from USD 3.28 billion in 2024 to USD 5.28 billion by 2030, driven by advances in healthcare technologies and increased investment in oncology research. Key areas explored include market penetration, development, diversification, competitive assessment, and product innovation. Challenges include high R&D costs and regulatory hurdles. Opportunities lie in personalized medicine and novel drug delivery systems.

EC approves Kisqali® (ribociclib) plus AI for HR+/HER2- early breast cancer, based on Phase III NATALEE trial showing 25.1% reduction in recurrence risk. Approval extends eligibility to more patients, addressing high risk of recurrence despite endocrine therapy.

The European Commission approved ribociclib (Kisqali) plus an aromatase inhibitor for adjuvant treatment of hormone receptor–positive, HER2-negative early breast cancer at high risk of recurrence, based on NATALEE trial data showing a 25% reduction in risk of invasive disease, recurrence, or death. The 3-year invasive disease–free survival rate was 90.4% with ribociclib vs 87.1% with AI alone.

The Gene Switch Market is projected to grow from USD 0.78 Bn in 2024 to USD 1.78 Bn by 2031, with a CAGR of 11.6%. CoherentMI's report provides a comprehensive analysis of market trends, competitive landscape, and key players like Novartis, Pfizer, and Gilead Sciences.

The Allergy Relieving Eye Drops Market is projected to grow from USD 1.51 billion in 2023 to USD 2.37 billion by 2032, driven by rising allergy prevalence, demand for non-invasive solutions, and advancements in eye drop formulations. Key markets include Canada, France, India, and UAE, with major companies like AbbVie, Johnson & Johnson, and Pfizer leading the industry.

The European Commission approved Novartis' Kisqali, in combination with an aromatase inhibitor, for the adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative breast cancer. This decision is based on the Phase III NATALEE trial results, showing a 25.1% decrease in disease recurrence risk. The approval follows the US FDA's recent approval for the same indication.

The global Next Generation Cancer Diagnostics market is projected to grow from $16.6B in 2023 to $64.6B by 2030, driven by increasing cancer prevalence, personalized medicine advancements, and regulatory approvals. Key technologies include liquid biopsy and NGS, with applications in screening, diagnostics, and treatment monitoring.

Novartis’ Kisqali approved by EC to reduce early breast cancer recurrence risk in HR-positive, HER2-negative patients, based on NATALEE trial results showing 25.1% reduction in recurrence risk with Kisqali plus endocrine therapy.

EC approves Kisqali (ribociclib) plus AI for HR+/HER2- EBC at high risk of recurrence, based on NATALEE trial results showing 25.1% reduction in disease recurrence risk with Kisqali plus ET vs. ET alone, consistent across subgroups.